The relationship between PD-L1 expression and the anaplastic variant of DLBCL is of increasing interest in clinical and research settings, particularly due to the relevance of PD-L1 as a target for immunotherapy. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.